ArticleFrontiers in endocrinology2026
Atherogenic index of plasma as a simple marker for NAFLD risk stratification in community-dwelling older adults: a cross-sectional study with incremental predictive value assessment.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The atherogenic index of plasma (AIP), calculated as log Methods: From 5,783 residents aged ≥65 years without significant alcohol consumption recruited in Zhanjiang, western Guangdong (2023-2024), 4,390 were enrolled after exclusions. NAFLD was diagnosed by ultrasonography. AIP was examined using multivariable logistic regression, restricted cubic splines, subgroup analyses, and trend tests with comprehensive confounder adjustment. Incremental predictive value was assessed through a multidimensional evaluation framework comprising ROC curves, calibration, decision curve analysis, net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Results: NAFLD prevalence was 42.7%, rising stepwise across AIP quartiles (22.4%, 36.9%, 50.1%, 61.3%; P for trend < 0.001). Each 1-unit increment in AIP was associated with a 6.13-fold higher NAFLD risk (OR 6.13, 95% CI 4.55-8.28) after full adjustment. Restricted cubic splines revealed a strictly linear, threshold-free association (P for nonlinearity = 0.714), consistent across age, residence, hypertension, and diabetes subgroups, with a statistically significant interaction by sex (P for interaction = 0.042). Adding AIP to a baseline clinical model improved discrimination (AUC from 0.786 to 0.811), calibration, clinical net benefit, and risk reclassification (categorical NRI 0.0997, IDI 0.0487; P< 0.001). Conclusions: AIP demonstrates an independent, linear relationship with NAFLD risk in community-dwelling older adults, exhibiting no discernible safe threshold. This low-cost, routine lipid-derived marker supports a "single-indicator, dual-prevention" strategy for simultaneous NAFLD screening and cardiometabolic risk stratification in primary care, challenging the conventional practice of relying solely on discrete lipid cut-offs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.